Marcus Bosenberg, MD, PhD
Anthony N. Brady Professor of Dermatology, Pathology and ImmunobiologyCards
Additional Titles
Director, Yale SPORE in Skin Cancer
Director, Yale Center for Immuno-Oncology
Co-Leader, Cancer Immunology, Yale Cancer Center
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Yale SPORE in Skin Cancer
Director, Yale Center for Immuno-Oncology
Co-Leader, Cancer Immunology, Yale Cancer Center
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Yale SPORE in Skin Cancer
Director, Yale Center for Immuno-Oncology
Co-Leader, Cancer Immunology, Yale Cancer Center
Contact Info
About
Titles
Anthony N. Brady Professor of Dermatology, Pathology and Immunobiology
Director, Yale SPORE in Skin Cancer; Director, Yale Center for Immuno-Oncology; Co-Leader, Cancer Immunology, Yale Cancer Center
Biography
Marcus Bosenberg MD, PhD, is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Cancer Immunology Program of Yale Cancer Center, Director of the Yale Center for Immuno-Oncology, Contact PI of the Yale SPORE in Skin Cancer, Director of the Center for Precision Cancer Modeling, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.
In his research, Dr. Bosenberg studies factors that regulate anti-cancer immune responses. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new cancer therapies, and how the immune system can be stimulated to fight cancer. He works to translate basic scientific findings into improvements in cancer diagnosis and therapy. He has published over 200 peer-reviewed articles and is a member of the Yale Cancer Center Executive Committee.
Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.
Appointments
Dermatology
ProfessorPrimaryImmunobiology
ProfessorSecondaryPathology
ProfessorSecondary
Other Departments & Organizations
- Cancer Immunology
- Computational Biology and Biomedical Informatics
- Dermatology
- Dermatopathology
- Human and Translational Immunology Program
- Immunobiology
- Immunology
- K12 Calabresi Immuno-Oncology Training Program (IOTP)
- Molecular Medicine, Pharmacology, and Physiology
- Pathology
- Pathology and Molecular Medicine
- Pathology Research
- Skin & Kidney Cancer Program
- SPORE in Skin Cancer
- Surgical Pathology
- Yale Cancer Center
- Yale Center for Immuno-Oncology
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Medicine
- Yale Stem Cell Center
- Yale Ventures
Education & Training
- Research Fellow
- Dana-Farber Cancer Institute (2002)
- Fellow
- Harvard Medical School Dermatopathology Training Program (2000)
- Chief Resident
- Brigham & Women's Hospital (1999)
- Resident
- Brigham & Women's Hospital (1998)
- Research Fellow
- University of Wisconsin (1996)
- MD
- Cornell University Medical College (1994)
- PhD
- Cornell University Medical College (1993)
- BA
- Cornell University (1986)
Research
Overview
Directs a National Cancer Institute funded melanoma research laboratory with interests in several aspects of melanoma biology including the cell biology and genetics of metastasis, prognostic and diagnostic markers and development of new therapeutic agents.
Medical Research Interests
ORCID
0000-0003-0166-1612
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Goran Micevic, MD, PhD
William Damsky, MD, PhD
Harriet Kluger, MD
Akiko Iwasaki, PhD
Kim Blenman, PhD, MS
Michael Girardi, MD, FAAD
Melanoma
Neoplasm Metastasis
Publications
2024
Setdb1-loss induces type-I interferons and immune clearance of melanoma.
McGeary M, Damsky W, Daniels A, Lang S, Xu Q, Song E, Huet-Calderwood C, Lou H, Paradkar S, Micevic G, Kaech S, Calderwood D, Turk B, Yan Q, Iwasaki A, Bosenberg M. Setdb1-loss induces type-I interferons and immune clearance of melanoma. Cancer Immunology Research 2024 PMID: 39589394, DOI: 10.1158/2326-6066.cir-23-0514.Peer-Reviewed Original ResearchConceptsT cell infiltrationMHC-I expressionType I interferonImmune clearanceCD8+ T cell-dependent mannerIncreased CD8+ T cell infiltrationCD8+ T cell infiltrationDecreased MHC-I expressionAnti-cancer immune responseT cell-dependent mannerCD8+ T cellsDecreased T-cell infiltrationComplete tumor clearanceImmunity to melanomaIncreased melanoma growthInflamed tumor microenvironmentLoss of SETDB1Type I interferon receptorTreatment of melanomaType I interferon signalingWhole-genome CRISPR screenEndogenous retrovirusesType I interferon expressionMetastatic diseaseTumor clearanceScavenger Receptor CD36 in Tumor-Associated Macrophages Promotes Cancer Progression by Dampening Type I Interferon Signaling.
Xu Z, Kuhlmann-Hogan A, Xu S, Tseng H, Chen D, Tan S, Sun M, Tripple V, Bosenberg M, Miller-Jensen K, Kaech S. Scavenger Receptor CD36 in Tumor-Associated Macrophages Promotes Cancer Progression by Dampening Type I Interferon Signaling. Cancer Research 2024 PMID: 39546763, DOI: 10.1158/0008-5472.can-23-4027.Peer-Reviewed Original ResearchConceptsTumor-associated macrophagesIFN-ITumor microenvironmentTumor growthHeterogeneous population of myeloid cellsPharmacological inhibition of CD36Population of myeloid cellsTumor cell quiescenceAnti-tumor immunityDelayed tumor growthTumor inflammatory microenvironmentElevated type I interferonReduced tumor growthMyeloid-specific deletionDeletion of CD36Type I interferon signalingInhibition of CD36Promote cancer progressionI interferon signalingIFN-I responseIFN-I signalingType I interferonScavenger receptor CD36TAM functionNatural suppressorUltra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
Li X, Liu T, Bacchiocchi A, Li M, Cheng W, Wittkop T, Mendez F, Wang Y, Tang P, Yao Q, Bosenberg M, Sznol M, Yan Q, Faham M, Weng L, Halaban R, Jin H, Hu Z. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. EMBO Molecular Medicine 2024, 16: 2188-2209. PMID: 39164471, PMCID: PMC11393307, DOI: 10.1038/s44321-024-00115-0.Peer-Reviewed Original ResearchConceptsMolecular residual diseaseCirculating tumor DNAWhole-genome sequencingCell-free DNAGenome sequenceDetection of molecular residual diseaseCirculating tumor DNA detectionResidual disease detectionConsistent with clinical outcomesVariant allele frequencyResidual diseaseMelanoma patientsMonitoring immunotherapyTumor DNAEsophageal cancerClinical outcomesColorectal cancerWGS technologiesAllele frequenciesCancerDNAAnalytical sensitivitySequenceImmunotherapyRelapseEnhanced intratumoral delivery of immunomodulator MPLA via hyperbranched polyglycerol-coated biodegradable nanoparticles
Chang J, Shin K, Lewis J, Suh H, Lee J, Damsky W, Xu S, Bosenberg M, Saltzman W, Girardi M. Enhanced intratumoral delivery of immunomodulator MPLA via hyperbranched polyglycerol-coated biodegradable nanoparticles. Journal Of Investigative Dermatology 2024 PMID: 39122142, DOI: 10.1016/j.jid.2024.07.019.Peer-Reviewed Original ResearchConceptsMonophosphoryl lipid ATumor microenvironmentImmunomodulatory agentsStimulation of anti-tumor immune responseEfficacy of monophosphoryl lipid AT-helper (Th)1 responsesAnti-tumor immune responseTumor-draining lymph nodesToxicity associated with systemic administrationImmune responseModel of malignant melanomaAgonist monophosphoryl lipid ABiodegradable nanoparticlesImmunogenic tumor microenvironmentAntitumor immune responseDraining lymph nodesSystemic side effectsNatural killer cellsGradual drug releaseKiller cellsAntitumor efficacyMalignant melanomaImproved survivalLymph nodesChemotherapeutic agentsDevelopment of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC)
Kashima S, Gupta R, Moritz V, Sadak K, Adeniran A, Humphrey P, Dinulescu D, Palmer D, Hammond S, Bosenberg M, Hurwitz M, Kenney P, Braun D. Development of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC). The Oncologist 2024, 29: s5-s6. PMCID: PMC11301923, DOI: 10.1093/oncolo/oyae181.008.Peer-Reviewed Original ResearchConceptsRCC tumor microenvironmentPatient-derived tumor modelsRenal cell carcinomaImmune checkpoint inhibitorsT cell functionPeripheral blood mononuclear cellsEnzyme-linked immunosorbent assayTumor microenvironmentT cellsFlow cytometryTumor fragmentsIFN-gTumor modelTumor samplesCytokine productionHealthy donor peripheral blood mononuclear cellsImpact of immune checkpoint inhibitorsAnti-PD-1 monoclonal antibodyDonor peripheral blood mononuclear cellsCD4+CD25+ regulatory T cellsCD8+ T cell populationsResection of renal cell carcinomaSurgical resection of renal cell carcinomaAnti-PD-1 antibodyMetastatic renal cell carcinomaThe Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms
Chen A, Sharma N, Patel P, Olivares S, Bahrami A, Barnhill R, Blokx W, Bosenberg M, Busam K, de La Fouchardière A, Duncan L, Elder D, Ko J, Landman G, Lazar A, Lezcano C, Lowe L, Maher N, Massi D, Messina J, Mihic-Probst D, Parker D, Redpath M, Scolyer R, Shea C, Spatz A, Tron V, Xu X, Yeh I, Yun S, Zembowicz A, Gerami P. The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms. The American Journal Of Surgical Pathology 2024, 48: 708-718. PMID: 38590014, DOI: 10.1097/pas.0000000000002226.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsDesmoplastic melanomaMelanocytic neoplasmsNext-generation sequencingInterobserver agreementDiagnostic accuracyHematoxylin and eosin sectionsImpact of next-generation sequencingDiagnostic scenariosMetastatic diseaseDesmoplastic tumorsMelanocytic tumorsMelanoma casesMelanoma geneticsFleiss' multirater kappaAccurate diagnosisNeoplasmsMelanomaAncillary toolDegree of improvementMultirater kappaDiagnosisGenomic findingsTumorGenome sequencing resultsPathologistsBRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms
Gerami P, Chen A, Sharma N, Patel P, Hagstrom M, Kancherla P, Geraminejad T, Olivares S, Biswas A, Bosenberg M, Busam K, de La Fouchardière A, Duncan L, Elder D, Ko J, Landman G, Lazar A, Lowe L, Massi D, Mihic-Probst D, Parker D, Scolyer R, Shea C, Zembowicz A, Yun S, Blokx W, Barnhill R. BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms. The American Journal Of Surgical Pathology 2024, 48: 538-545. PMID: 38525831, DOI: 10.1097/pas.0000000000002194.Peer-Reviewed Original ResearchMeSH Keywords and Concepts
2023
1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma
Micevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn H, Sefik E, Cheung J, Hornick N, Aizenbud L, Joshi N, Kluger H, Iwasaki A, Bosenberg M, Flavell R. 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma. 2023, a1133-a1133. DOI: 10.1136/jitc-2023-sitc2023.1025.Peer-Reviewed Original ResearchManipulating mitochondrial electron flow enhances tumor immunogenicity
Mangalhara K, Varanasi S, Johnson M, Burns M, Rojas G, Esparza Moltó P, Sainz A, Tadepalle N, Abbott K, Mendiratta G, Chen D, Farsakoglu Y, Kunchok T, Hoffmann F, Parisi B, Rincon M, Vander Heiden M, Bosenberg M, Hargreaves D, Kaech S, Shadel G. Manipulating mitochondrial electron flow enhances tumor immunogenicity. Science 2023, 381: 1316-1323. PMID: 37733872, PMCID: PMC11034774, DOI: 10.1126/science.abq1053.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsElectron transport chainMethylation-controlled J proteinMitochondrial electron transport chainElectron flowMitochondrial electron flowJ-proteinsEpigenetic activationTransport chainMitochondrial respirationTumor growthPresentation genesElectron entryNoncancer cellsMelanoma tumor growthCommon mechanismTherapeutic potentialGenesRelative contributionProteinGrowthKnockoutAntigen presentationRespirationT cell-mediated killingExpressionCombinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.
Krykbaeva I, Bridges K, Damsky W, Pizzurro G, Alexander A, McGeary M, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss S, Olino K, Kaech S, Kluger H, Miller-Jensen K, Bosenberg M. Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance. Cancer Immunology Research 2023, 11: 1332-1350. PMID: 37478171, DOI: 10.1158/2326-6066.cir-22-0699.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsPD-1 resistanceDendritic cellsTumor regressionAnti-PD-1 resistanceActivates Dendritic CellsCytokine secretion profilingSystemic cytokine profileTriple therapy combinationInnate immune activationAdaptive immune responsesComplete tumor regressionMajority of miceSignificant clinical challengeMouse melanoma modelT cell activationAgonistic CD40Checkpoint inhibitorsDC subsetsTriple therapyCytokine profileImmune activationCombinatorial immunotherapyTherapy combinationsT cellsClinical challenge
Academic Achievements & Community Involvement
honor Basic Science Research Prize
Yale School of Medicine AwardYale Cancer CenterDetails03/24/2022United States
Clinical Care
Overview
Marcus Bosenberg, MD, PhD, specializes in skin pathology, identifying skin cancers, autoimmune skin disorders and skin infections under the microscope. “As a dermatopathologist, I enjoy being part of a team that works hard to provide the best available health care for each patient,” he says.
An expert in deciphering even the slightest variations in skin cells, Dr. Bosenberg and other members of the Yale Medicine dermatopathology team evaluate biopsy samples sent to the lab from doctors all over the country. With challenging cases, Dr. Bosenberg and his colleagues collaborate during a daily consensus conference at a multi-head microscope to ensure the right diagnosis is made. “I am always excited to work out challenging clinical and research problems,” he says.
A professor of dermatology and pathology at Yale School of Medicine, he leads a melanoma research laboratory and is a co-leader of a genetics and genomics program. His research focuses on genetic and cellular changes that result in melanoma, the leading cause of skin cancer deaths, as well as new therapies for melanoma.
“Through our research, we are trying to find better ways to diagnose and treat skin cancer,” says Dr. Bosenberg.
Clinical Specialties
Board Certifications
Dermatopathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2001
Anatomic Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2000
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
- August 28, 2023
1st ARPA-H Grant: mRNA-Based Anti-Cancer and Anti-Microbial Vaccine Development
- August 10, 2023
Simon Roy, MD Awarded Grant for Diversifying Acral Melanoma Research
- July 27, 2023
Yale Scientists Identify Immune Cells Critical for Immunologic Memory for Melanoma
- July 18, 2023
New Funding to Support Kidney Cancer Research in Braun Lab
Get In Touch
Contacts
Locations
Laboratory for Medicine and Pediatrics (LMP)
Academic Office
15 York Street, Rm LMP 5036
New Haven, CT 06510
Clinical Inquiry
203.737.3484Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.